Tyrosine kinase inhibitors (TKIs) are small molecules that inhibit HER2 kinase activity by competing with ATP at the intracellular domain, thereby blocking PI3K/AKT and MAPK signaling that drive tumor growth and survival. Here, AKT1 is linked to neoplasm.